IDEXX Laboratories, Inc. · IDXX · Next earnings

IDEXX Laboratories, Inc. reports Monday, Nov 2, 2026

IDXX reports before market open with consensus EPS at $3.71 and revenue at $1.19B. Last quarter: IDEXX Q1 2026: Beat-and-Raise as Diagnostics Growth Outpaces Slowing Vet Visits

Reports Before market open43 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $3.71 Calendar consensus
Consensus revenue $1.19B Calendar consensus
Report date Nov 2, 2026 Monday, date estimated
Session Before market open 43 days away

Where IDXX left off: FY2026 Q1

Full report

IDEXX Q1 2026: Beat-and-Raise as Diagnostics Growth Outpaces Slowing Vet Visits

EPS surprise +1.8% Reported $3.47 vs $3.41
Revenue surprise +2.0% Reported $1.14B vs $1.12B
Stock move -0.0% Event window
Subsequent drift -0.4% Up to 20 sessions

IDEXX raised its full-year fiscal 2026 outlook following the Q1 beat. The prior quarter (Q4 2025) guidance had projected 7-9% revenue growth, 32-32.5% operating margin, and EPS of $14.29-$14.80. The guidance sentiment shifted from maintained to raised, reflecting management's increased confidence after the strong first quarter. Specific updated numerical ranges were not detailed in the supplied transcript analysis, but the direction is clearly upward.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Continued decline in wellness and discretionary veterinary visits could pressure top-line growth.
  • Macro-economic pressures, including fuel prices, may affect pet-owner discretionary spending.
  • Supply-chain challenges in the Middle East are impacting the Water business.
  • Potential slowdown in instrument placement growth as the installed base matures and laps strong prior-year comps.
  • One-time items, including a $5 million equity-investment loss, may affect earnings comparability.

Questions analysts left open

  • Pacing of inVue Dx placements versus the 5,500-unit annual target.
  • Assumptions behind the modest decline in U.S. clinical visits.
  • Timing and scale of the full, unrestricted F&A launch.
  • Impact of pricing versus volume on CAG Diagnostics outlook.
  • Supply-chain constraints in the Water business and their effect on guidance.

Ask FN2 about IDXX next report

Transcript, numbers and history already loaded
What should I watch for in IDXX's next earnings report?How did IDXX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into IDXX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the IDXX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent IDXX quarters

All IDXX earnings
-0.0%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.